Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14684712 | 0.95 | MAPT (0.38) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL15517158 | 0.94 | TDP1 (0.39) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL11093696 | 0.88 | MAPT (0.53) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL11101641 | 0.88 | MAPT (0.49) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL16979623 | 0.85 | MAPT (0.39) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL15520246 | 0.84 | TDP1 (0.42) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL15518487 | 0.84 | TDP1 (0.45) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL11094728 | 0.83 | MAPT (0.64) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL9019294 | 0.83 | MAPT (0.35) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL15518472 | 0.80 | PTPN2 (0.33) | MAPTTDP1LMNAPGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| WO-2025224119-A1 | METHOD OF ENRICHING A CELL POPULATION CONTAINING INTACT AND DAMAGED CELLS IN A LIQUID MEDIUM | TrophoSYS GmbH (DE) | 2025-10-30 | — | — | WO | claimed |
| CN-119656319-A | Iron death inhibitors for improving liver toxicity of GPR40 agonist TAK-875 | 张宏全 | 2025-03-21 | — | — | CN | claimed |
| EP-4494639-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | Pluto Inc. (KR) | 2025-01-22 | — | — | EP | claimed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-09-12 | — | — | US | claimed |
| WO-2023177128-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | 주식회사 플루토 | 2023-09-21 | — | — | WO | claimed |
| US-20210275600-A1 | METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES | Tets, Viktor Veniaminovich (US) | 2021-09-09 | — | — | US | claimed |
| EP-3400971-B1 | ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2021-08-04 | — | — | EP | claimed |
| EP-3852774-A1 | METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES | Tets, Viktor, Veniaminovich (US) | 2021-07-28 | — | — | EP | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| EP-0750496-A1 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-01-02 | — | — | EP | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1995024894-A9 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | — | 1995-10-26 | — | — | WO | claimed |
| WO-1995024894-A2 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-21 | — | — | WO | claimed |
| EP-0038160-B1 | QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-19 | — | — | EP | claimed |
| US-4393075-A | SLOW-REACTING-SUBSTANCE OF ANAPHYLAXIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-07-12 | — | — | US | claimed |
| EP-0038160-A1 | Quinone compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-10-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | ALOX5, ALOX15, ALOX15B | MAPT 1521/4885TDP1 858/4885LMNA 3601/4885 |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | MAPT 3742/4885TDP1 2982/4885LMNA 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.